Sergliflozin etabonate_product_DataBase

Bioactivity	Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes[1].
In Vivo	Sergliflozin etabonate (1、3、10、30 mg/kg；口服；一次) 以剂量依赖性方式显着降低 KK-Ay 小鼠的非空腹血糖水平[1]。Sergliflozin etabonate (1.7、8.4、45.7 mg/kg饲料含有 0.001、0.005 和 0.025% sergliflozin etabonate；进食；每天服用，持续 9 周) 以剂量依赖的方式降低非空腹血糖水平并降低肝脏中的甘油三酯含量在 KK-Ay 小鼠中[1]。 Animal Model:
Name	Sergliflozin etabonate
CAS	408504-26-7
Formula	C23H28O9
Molar Mass	448.46
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Katsuno K, et al. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104.

PeptideDB